Laboratory systems and networking solutions technology provider BATM’s subsidiary Ador Diagnostics is developing and marketing two in-vitro molecular diagnostics solutions.

Ador has received its first commercial order from an Italian distributor of molecular biology and genomics – meaning it will deliver the NATlab reader and cartridges for the identification of meningitis in the second half of 2020.

Ador’s NATlab molecular biology solution provides diagnosis of bacterial, viral or fungal infections, within approximately 15-90 minutes, using DNA sampling. The system is designed to be used at the point-of-care as well as in hospital labs. Ador believes that NATlab will allow medical practitioners to provide quicker and more efficient treatment.

This first commercial order for the new system follows lab testing and the award of over 40 global patents, including in Europe and the US, with more pending. The first models of NATlab are expected to go into final trials in hospitals in the first half of this year, with the initial system having been already delivered this month.

Dr Zvi Marom, chief executive officer of BATM, said: “We are delighted that Ador has received the first commercial order for the NATlab system, which is an important milestone. Meningitis is a leading infectious cause of childhood death – and speed of identification and treatment is vital. We are proud that our rapid sample-to-answer solution will help medical practitioners to quickly and efficiently diagnose the specific infection and administer the required treatment.

“We believe NATlab will transform the infectious disease diagnostics market and we have already received extremely positive feedback and significant interest from several leading medical institutions that are testing the solution. Ador is also working alongside prominent academic and research institutions, including in the UK, to develop more panels for the identification of further diseases. We look forward to reporting on Ador’s progress.”